Aryeh Jason, a director at Ligand Pharmaceuticals Inc, has reported several stock transactions in a recent SEC filing. The transactions, which occurred on October 30 and November 2, 2026, involve the sale of a total of 2,000 shares of Ligand Pharmaceuticals. This update is significant as it reflects changes in Jason's ownership structure and may attract attention within the pharmaceutical industry.

Background

Ligand Pharmaceuticals Inc, identified by the CIK 0000886163, operates within the pharmaceutical preparations industry. The company is incorporated in Delaware and is known for its innovative approaches in life sciences. Its fiscal year ends on December 31. Jason Aryeh, who has been involved with Ligand, filed this report as part of his obligations under the SEC regulations.

What the Filing Says

The SEC filing, accession number 0001376960-26-000005, details multiple transactions by Aryeh Jason. On October 30, he sold 50 shares at $317.74, 50 shares at $318.23, 52 shares at $320.24, 1,209 shares at $320.42, and 50 shares at $320.49. Additionally, on November 2, he sold 700 shares at a weighted average price of $320.43. Following these transactions, his ownership of Ligand's common stock decreased significantly.

Impact

This change in ownership may affect various stakeholders, including investors and analysts who monitor insider trading activities. The pharmaceutical industry, particularly companies like Ligand Pharmaceuticals, may experience heightened scrutiny regarding insider transactions, which can influence market perceptions and investor confidence.

What's Next

The filing does not say what happens next.